neovascular glaucoma
Conditions
Interventions
intervention group:The intervention group received intravitreal injection of conbercept 0.05ml and subconjunctival injection of conbercept 0.1ml before compound trabeculectomy
control group:The control line before the compound trabeculectomy conventional glass cavity injection compaq heap
Sponsors
Department of Ophthalmology, the Second Affiliated Hospital of Harbin Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1.Patients were willing to be followed up according to the time specified in the study by signing the informed consent; 2.age >=18 years old, regardless of gender; 3.The target eye must meet the following requirements: Neovascular glaucoma, angle-closure glaucoma stage (stage III), poor IOP control (>=25mmHg) with maximum dose of topical and systemic IOP-lowering drugs, and visual acuity = light perception.
Exclusion criteria
Exclusion criteria: 1.the patients with primary glaucoma, inflammatory or other eye diseases caused by secondary glaucom 2.patients with active or chronic uveitis 3.within 4 months after passing triamcinolone acetonide injection 4.low intraocular pressure (< 6 MMHG), eye disease 5.Ocular disease (either eye) : intravitreal anti-VEGF therapy within 3 months 6.history of stroke, history of myocardial infarction and/or cerebrovascular disease, history of transient cerebral ischemia, active disseminated intravascular coagulation, and significant bleeding tendency within 6 months before enrollment 7.the fluorescein sodium has a history of allergic reaction or allergic, to treatment or diagnosis with protein products has a history of allergies 8.patients with a confirmed systemic immune disease 9.Patients with any uncontrolled clinical illness (such as severe psychiatric, neurological, cardiovascular, respiratory diseases and malignant tumors) 10.patients with high blood pressure control is not ideal (defined as after treatment with antihypertensive drugs, systolic blood pressure is still 160 MMHG or higher or diastolic blood pressure is still 100 MMHG or higher) 11.blood glucose control is not ideal with diabetes (defined as the fall blood sugar after drug treatment, fasting plasma glucose or greater tendency for 11.1 / L) 12.history of surgery within 1 month, and/or current unhealed wounds, ulcers, fractures, etc 13.systemic use of anti-VEGF agents (e.g., bevacizumab) within 6 months 14.Women who are pregnant or preparing to become pregnant
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| IOP(intraocular pressure); | — |
Secondary
| Measure | Time frame |
|---|---|
| Regression and recurrence of iris surface neovascularization (NVI)/Angle neovascularization (NVA); | — |
Countries
China
Contacts
Public ContactShaowei Wang
The second affiliated hospital of Harbin medical university eye
Outcome results
None listed